Posted by Michael Wonder on 27 Sep 2024
FDA approves drug with new mechanism of action for treatment of schizophrenia
26 September 2024 - Today, the US FDA approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.
